DaVita To Pay Record $495M To Settle Kidney Drug FCA Suit
DaVita Inc. said Monday it set aside $495 million as part of a tentative deal to resolve a False Claims Act whistleblower suit for allegedly bilking taxpayers for reimbursement of intentionally...To view the full article, register now.
Already a subscriber? Click here to view full article